瑞士辉凌制药Ferring Pharmaceuticals www.ferring.com
辉凌集团于1950年由Frederik Paulsen博士创办，是世界上首家生产人工合成肽的公司之一, 并在不同的治疗领域上，包括泌尿科、生殖医学、妇产科、胃肠道疾病和内分泌系统疾病等，开发各类创新药品。
辉凌集团的总部设于瑞士，在瑞士、瑞典、丹麦、德国和捷克共和国均设有生产厂房，研发中心则在英国和美国，分支机构遍布世界40多个国家。过去的20年间，辉凌集团保持每年约20%的增长。
于九十年代初，FERRING在香港成立辉凌制药有限公司，作为亚太区总部。在这十数年，成功将产品引进亚洲区内多主要市场，令更多的病人获得最新及最适当的药物治疗。
辉凌中国于1996年成立， 令辉凌集团成为其中一家最早获准在国内设立全资拥有企业的外国公司。为配合辉凌集团的发展计划，辉凌中国于2003年在广东省中山港国家健康基地兴建了一所占地20,000平方尺的高科技生产厂房，总投资额为一千四百伍拾万美元，厂房于2005年3月开幕后，成为辉凌集团在亚太区第一家生产厂房。
一直以来，FERRING与很多大学、医疗机构和其他研究所都有着紧密联系，共同进行研究工作。我们深信，以我们日渐扩展的网络，FERRING的产品将令更多病人受惠，从而实现我们的承诺：辉凌制药 — 以科学造福人类。

总部位于瑞士的Ferring医药在全球范围内设销售和生产点，在哥本哈根还有一个大型研发中心。全球有超过2700名员工，并以缩氨酸产品闻名于世。 

辉凌医药咨询（上海）有限公司
上海市浦东新区源深路1088号 
葛洲坝大厦10楼01-03单元 
邮政编码：200122
电话：021-38529666
传真：021-38529661
电子邮件：info.china@ferring.com
北京咨询分公司
北京市东城区建国门内28号
民生金融中心A座11层03室
电话：010- 85295326
传真：010- 85295336
电子邮件：info.china@ferring.com
北京发展中心
北京市东城区建国门内28号
民生金融中心A座11层03室
电话：（86）10 8529-5338
传真：（86）10 8529-5335
电子邮件：info.china@ferring.com
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of infertility, obstetrics, urology, gastroenterology, endocrinology and osteoarthritis.
The company’s research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body’s own terms to enable doctors to combat numerous diseases and medical conditions.
The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world.
Ferring has its own production facilities in several European countries, in South America, Israel and China. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
Ferring’s marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 45 countries and employ more than 3500 people throughout the world, while treatments are available in more than 70 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.
Ferring’s R&D projects complement Ferring’s product portfolio and will add a new generation of products to some of the company’s most successful specialty brands. R&D facilities are located in Denmark, Israel and California, USA.
Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.